Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.

Literature DB >> 12604559

Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.

Dianne B Hoellman¹, Gengrong Lin, Lois M Ednie, Ashok Rattan, Michael R Jacobs, Peter C Appelbaum.

Abstract

For 260 pneumococcal and 266 staphylococcal strains, ranbezolid MICs ranged from < or =0.06 to 4 micro g/ml. The MICs for pneumococci were similar irrespective of the strains' beta-lactam, macrolide, or quinolone susceptibilities, and ranbezolid MICs for coagulase-negative staphylococci were lower than those for Staphylococcus aureus. Ranbezolid was bacteriostatic against pneumococci. Ranbezolid MICs were similar to or lower than those of linezolid. Vancomycin and quinupristin-dalfopristin were also very active.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2003 PMID： 12604559 PMCID： PMC149337 DOI： 10.1128/AAC.47.3.1148-1150.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

19 in total

Review 1. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

Authors: D M Livermore
Journal: J Antimicrob Chemother Date: 2000-09 Impact factor: 5.790

2. In vitro activity of linezolid against staphylococci.

Authors: C Cuny; W Witte
Journal: Clin Microbiol Infect Date: 2000-06 Impact factor: 8.067

3. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.

Authors: K Hiramatsu
Journal: Am J Med Date: 1998-05-29 Impact factor: 4.965

4. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors: E Cercenado; F García-Garrote; E Bouza
Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790

5. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

Authors: C J Henwood; D M Livermore; A P Johnson; D James; M Warner; A Gardiner
Journal: J Antimicrob Chemother Date: 2000-12 Impact factor: 5.790

6. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

Authors: R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal: Diagn Microbiol Infect Dis Date: 1999-06 Impact factor: 2.803

Review 7. Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors: P C Appelbaum
Journal: Clin Infect Dis Date: 1992-07 Impact factor: 9.079

8. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors: D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

Review 9. Optimal treatment of complicated skin and skin structure infections.

Authors: R L Nichols
Journal: J Antimicrob Chemother Date: 1999-09 Impact factor: 5.790

Review 10. Oxazolidinones: a review.

Authors: D I Diekema; R N Jones
Journal: Drugs Date: 2000-01 Impact factor: 11.431

13 in total

1. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors: Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191

2. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry.

Authors: Nuno Cerca; Silvia Martins; Filipe Cerca; Kimberly K Jefferson; Gerald B Pier; Rosário Oliveira; Joana Azeredo
Journal: J Antimicrob Chemother Date: 2005-06-24 Impact factor: 5.790

3. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors: E E McKee; M Ferguson; A T Bentley; T A Marks
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

4. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors: Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2005-10 Impact factor: 5.191

5. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors: Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191

6. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors: Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191

7. Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.

Authors: Vandana Kalia; Rajni Miglani; Kedar P Purnapatre; Tarun Mathur; Smita Singhal; Seema Khan; Sreedhara R Voleti; Dilip J Upadhyay; Kulvinder Singh Saini; Ashok Rattan; V Samuel Raj
Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191